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Letter to the Editor
PHANTOM HCG AND CLINICAL MANAGEMENT
To the Editor:
The measurement of apparent but spurious human chorionic gonadotropin (hCG) has been reported in
the literature over the last three decades, and has recently been referred to as “phantom hCG”. Such false-
positive results have led to some women being diagnosed with gestational trophoblastic disease (GTD)
and undergoing a variety of diagnostic procedures, chemotherapy, hysterectomy, and other surgical
procedures before it is recognized that the test is giving spurious results. It is relatively rare but immuno-
assay interference is still an important problem that can result in medical-legal or malpractice issues.
hCG is produced in pregnancy, in GTD, and in men with testicular germ cell malignancies. It is a perfect
tumor marker for GTD with 100% sensitivity and specificity. Immunoassay is such a beautiful analytical
technique. hCG assay has revolutionized the management of ectopic pregnancy and GTD and is now
capable of detecting the presence of a pregnancy before a missed menstrual period. In most cases, false-
positive hCG is discovered at the time of an incidental serum pregnancy test, as part of a check-up, before
surgery, or before a diagnostic procedure. Persistent low hCG results in the range of 100–1000 mIU/mL
over 2–6 weeks may be confused with an ectopic pregnancy and lead to methotrexate therapy or surgical
intervention, including salpingectomy. It is vital to remember that a test is always a test. False-positive and
false-negative results can occur with any specimen. Caution should be exercised when clinical findings and
laboratory results are discordant. The ability of laboratory measurements to guide the clinician
appropriately in every circumstance is limited [1]. Certain individuals have circulating factors in their
serum that interact with the hCG antibody, the most common of which are heteophile antibodies. These
are human antibodies directed against animal-derived antigens used in immunoassays. People with
heteophile antibodies might have unusual results in a number of different kinds of assays.
False-positive serum hCG results are estimated to occur in 1/1,000 to 1/10,000 tests. Using two-site
immunometric assays, the frequency with one such assay was reported to be as low as 1/1,000,000 tests
[2]. Most false-positive results are due to interference by non-hCG substances (especially human
luteinizing hormone, hLH, and anti-animal immunoglobulin antibodies) and the detection of pituitary
hCG. Clinically significant false-positive results are rare. Misleading results are usually seen with values
below 1,000 mIU/mL. Causes of false-positive hCG measurements have been summarized into four areas
[3]: measurement of pituitary hCG-like substance; production of free hCG ` -subunit; interference by non-
hCG substances, including hLH or hLH `-subunit, both species-specific and heterophilic anti-animal
immunoglobulin antibodies, rheumatoid factor, anti-hCG antibodies, and nonspecific serum factors;
and assay issues such as carryover by positive displacement pipettes and contaminants that affect label
detection (radioactive iodine or fluorophores).
To err is human, therefore an immunoassay may fail for the same reasons as any other laboratory test.
Erroneous results for analytes may be reported due to sample mix-up, mislabeling, etc. Also, sample
quality may affect some immunoassay results (e.g. presence of overt hemolysis, hyperbilirubinemia,
lipemia).
Characteristics of false-positive hCG measurements include: low-level positive result (generally <
1,000 mIU/mL and usually < 150 mIU/mL); positive serum but negative urine; serial dilutions of serum
that are not parallel to the hCG standard and yield higher or lower levels of hCG when multiplied by
dilution factor; positive hCG results that are not consistent with clinical or surgical findings; no
substantial changes in levels that were measured in serial blood samples, even after therapeutic
procedures; and negative results in a different type of quantitative hCG assay [3]. Therefore, when there
are discordant hCG results, the following steps are recommended [3]: measure urinary hCG, re-measure
the hCG concentration using a different method, look for parallelism to the hCG standard in serial
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dilutions of the serum, add normal mouse serum or other animal serum to the assay, test for anti-hCG
antibodies, and measure hCG concentrations in several days or weeks.
Heteophile (or heterophilic) antibodies are present in human serum and recognize the animal
immunoglobulins usually employed in commercial immunoassays (e.g. those derived from mice or
rabbits). In sandwich-type immunoassay formats, these antibodies have the ability to link the capture and
detection antibody without the presence of antigen, thus leading to false-positive results. In order to
eliminate most of the interference, animal immunoglobulins such as rabbit, goat, or mouse immuno-
globulin, or proprietary reagents developed by companies, are added to the reagent mixture.
The management of women with persistent low hCG results should be emphasized. The USA hCG
Reference Service is a consulting service with a specialized clinical laboratory aiding physicians in the
interpretation of conflicting or misrepresentative hCG results. Of 189 patients with persistent low levels
of hCG but no evidence of pregnancy or tumor, quiescent GTD was identified in 121 cases. Another 61
cases had false-positive hCG and seven had low levels of hCG of pituitary origin. A total of 128 patients
(77/121 with quiescent GTD, 48/61 with false-positive hCG, and 3/7 with pituitary hCG) had undergone
various therapies ranging from chemotherapy to hysterectomy [4]. Unfortunately, the number of
needlessly treated cases referred to the Reference Service is increasing. The observations of the Reference
Service for 134 cases with persistent low hCG results have been reviewed, and the appropriate
management of those presenting with persistent low hCG results reported. In a patient with a recent or
remote history of hydatidiform mole or GTD, the first step is to confirm the diagnosis using a different
laboratory and hCG test. If results are very different (more than twofold), then a false-positive hCG result
is likely. If the patient is over 45 years old or post-oophorectomy, then pituitary hCG should be considered
as the likely cause, regardless of history, and can be confirmed with 2 weeks or so of combination
estrogen–progesterone therapy, which suppresses hCG in patients with this diagnosis. The diagnosis of
quiescent disease can be confirmed by showing the absence of hyperglycosylated hCG (< 0.3 ng/mL). This
test is approved by the US Food and Drug Administration and is readily available at national clinical
laboratories (Nichols Institute Laboratories, invasive trophoblast antigen, ITA, test) [5].
hCG is a glycoprotein composed of two dissimilar subunits (_ and `) joined non-covalently. It is not
only heterogeneous in peptide structure but also in combination of subunits and in the structure of
carbohydrate side chains. Common hCG-related molecules in serum samples include regular hCG,
hyperglycosylated hCG (ITA), nicked hCG, nicked ITA, hCG missing the `-subunit C-terminal extension,
free _-subunit, free `-subunit, free `-subunit missing the C-terminal extension, hyperglycosylated
free `-subunit, and nicked free `-subunit. The same molecules plus `-core fragment are present in urine
samples. While ITA and regular hCG predominate in pregnancy samples, one of these multiple hCG-
related molecules may be the principal source of immunoreactivity in GTD, gestational trophoblastic
neoplasm, choriocarcinoma, and placental site tumor cases as well as in testicular cancer and germ cell
tumor. As such, it is critical to appropriately detect all these isoforms in the management of these diseases.
Only two tests, the Immulite (DPC, Inc., Los Angeles, CA, USA) and UK radioimmunoassay (RIA; used
at Charing Cross Hospital, London) appropriately detect all these hCG-related molecules. False-positive
hCG results are a major problem in the management of GTD and cancer. A proportion of false-positive
samples with the AxSym test (Abbott Laboratories, Inc., Chicago, IL, USA) can also be falsely positive with
the UK RIA, but none are falsely positive with the Immulite test. Thus, the Immulite/Immulite 2000 is the
only appropriate assay for monitoring patients with GTD or cancer [6]. In response to the false-positive
hCG test problem, Abbott Laboratories added warning and limitation notices to its instruction manual
in 2000. It is noted in these warnings that this test should only be used for pregnancy and not for GTD.
In laboratories using the AxSym test, it is recommended that twofold dilution is a minimum to prevent
a false-positive result [7].
In conclusion, if the hCG result is inconsistent with, or unsupported by, clinical evidence, results
should be confirmed using an alternative hCG assay. This may include the qualitative hCG testing of urine.
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Results may also be confirmed by performing serial dilution of the sample. In other words, for diagnostic
purposes, results should be used in conjunction with other data, such as symptoms, results of other tests,
and clinical impressions. Remember that an elevated serum hCG, for example, more than 25 mIU/mL,
may represent a normal pregnancy and it’s complications such as abortion or ectopic pregnancy, a GTD
or tumor, and a possibly false-positive or so-called phantom hCG.
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